MHRA appoints two directors
This article was originally published in Scrip
Executive Summary
TheMHRA, the UK medicines regulator, has named two new non-executive directors. Professor Barrington Furr retired from AstraZeneca in 2005 after more than 33 years with the company and its earlier incarnations. He lists consulting work for venture capital and biotechnology companies among his potential conflicts of interest, as well as work for Almirall and his role as a trustee of the Breast Cancer Campaign. Professor Vincent Lawton held senior positions at Merck Sharp and Dohme in Europe and North America in his 26 years with the company, and he continues to own stock and stock options. He is a trustee of the Association of the British Pharmaceutical Industry.